Rhythm Pharmaceuticals Netherlands

Company snapshot

Rhythm Pharmaceuticals Netherlands maintains 73 tracked programs across Heart Failure, Atrial Fibrillation, Hypothalamic Obesity, Paroxysmal Atrial Fibrillation, Syncope, Tachycardia, Ventricular, Acute Myocardial Infarction, Obesity, Overweight, Bardet-Biedl Syndrome, Arrhythmia, Cardiac, Hypertension. Momentum score: 20/100 (30-day delta: n/a). Public registry data covers pipeline phase, clinica

• 2 approved product(s) across US/EU regulatory metadata.
• 73 active pipeline program(s) linked via ClinicalTrials.gov.
• 12 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Rhythm Pharmaceuticals Netherlands. Not investment advice.

• Peer + 0 momentum

  Boehringer Ingelheim

  TA overlap score 50

• Peer + 0 momentum

  NovoThirteen

  TA overlap score 38.8

• Peer + 0 momentum

  Quantum Pharmaceuticals

  TA overlap score 23.6

• Peer + 0 momentum

  Yung Shin Pharmaceutical

  TA overlap score 22

• Peer + 0 momentum

  Aspire Biopharma Holdings

  TA overlap score 21.6

Recent activity

Latest pipeline, patent, and corporate events for Rhythm Pharmaceuticals Netherlands.

1. Jun 8, 2026 Clinical update

   20061016-V2 — Approved

2. Jun 8, 2026 Clinical update

   KCHRF-DASH-AF-0002 — Approved

3. Jun 8, 2026 Clinical update

   Use of an Implantable Loop Recorder — Approved

4. Jun 8, 2026 Clinical update

   Single Site Pacing — Phase 2

5. Jun 8, 2026 Clinical update

   Setmelanotide — Phase 1

View all clinical trial activity →

• What is Rhythm Pharmaceuticals Netherlands?

  Matisse Pharmaceuticals is a pharma organization headquartered in geleen, NL. It trades on NYSE under ticker RYTM. Primary therapeutic focus areas include Heart Failure, Atrial Fibrillation, Hypothalamic Obesity, Paroxysmal Atrial Fibrillation, Syncope. NovaPharmaNews links 73 cl

• Is Rhythm Pharmaceuticals Netherlands publicly traded?

  Yes. Rhythm Pharmaceuticals Netherlands is listed with ticker RYTM on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Rhythm Pharmaceuticals Netherlands develop or market?

  We link 38 drug profile(s) where Rhythm Pharmaceuticals Netherlands is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc#company-drugs.

• What are the latest developments for Rhythm Pharmaceuticals Netherlands?

  In the last 12 months our linked public records show 73 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Rhythm Pharmaceuticals Netherlands focus on?

  Rhythm Pharmaceuticals Netherlands focuses on Heart Failure, Atrial Fibrillation, Hypothalamic Obesity based on our analysis of their pipeline programs and drug development activities.